SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer

I Pergolini, S Crippa, Matteo Salgarello, G Belfiori, S Partelli, G Ruffo, A Pucci, Giuseppe Zamboni, M Falconi

Research output: Contribution to journalArticle

Abstract

Background: (18)fluoro-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) might be a useful tool in the management of pancreatic ductal adenocarcinoma (PDAC). Aims: The aim of this study was to analyze maximum standard uptake value (SUVmax) after 18FDG-PET/CT as predictor of survival outcomes and method to determine treatment strategies. Methods: A consecutive series of patients who underwent preoperative 18FDG-PET/CT and subsequent resection for PDAC were retrospectively reviewed. Patients who underwent neoadjuvant chemotherapy were excluded. Results: 46 patients were included in the analysis. Median follow-up was 27 months (4-67). Patients who recurred within 12 months showed a significantly higher preoperative median SUVmax (8.1 vs 6.1, p = 0.039). Receiver operating characteristics (ROC) curves for disease-free survival (DFS) and disease-specific survival (DSS) identified SUVmax of 6.0 as optimal cut-off. Multivariate analysis showed that SUVmax ≥ 6.0 was an independent predictor of poor DFS (HR 2.288, p = 0.024) and DSS (HR 4.875, p. <. 0.001). The combination of SUVmax ≥6.0 with CA19.9 ≥200. U/ml was significantly associated with survival outcomes in comparison to patients without concordantly elevated values. Conclusion: SUVmax ≥6.0 is an independent predictor of DFS and DSS in resected PDAC. 18FDG-PET/CT might be considered in the preoperative evaluation of patients with pancreatic cancer. © 2017 Editrice Gastroenterologica Italiana S.r.l.
Original languageEnglish
Pages (from-to)84-90
Number of pages7
JournalDigestive and Liver Disease
Volume50
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Deoxyglucose
Pancreatic Neoplasms
Survival
Disease-Free Survival
Adenocarcinoma
Therapeutics
ROC Curve
Positron Emission Tomography Computed Tomography
Multivariate Analysis
Drug Therapy

Cite this

SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. / Pergolini, I; Crippa, S; Salgarello, Matteo; Belfiori, G; Partelli, S; Ruffo, G; Pucci, A; Zamboni, Giuseppe; Falconi, M.

In: Digestive and Liver Disease, Vol. 50, No. 1, 2018, p. 84-90.

Research output: Contribution to journalArticle

@article{e1fcc174259e422ba29b6678f4fa2077,
title = "SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer",
abstract = "Background: (18)fluoro-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) might be a useful tool in the management of pancreatic ductal adenocarcinoma (PDAC). Aims: The aim of this study was to analyze maximum standard uptake value (SUVmax) after 18FDG-PET/CT as predictor of survival outcomes and method to determine treatment strategies. Methods: A consecutive series of patients who underwent preoperative 18FDG-PET/CT and subsequent resection for PDAC were retrospectively reviewed. Patients who underwent neoadjuvant chemotherapy were excluded. Results: 46 patients were included in the analysis. Median follow-up was 27 months (4-67). Patients who recurred within 12 months showed a significantly higher preoperative median SUVmax (8.1 vs 6.1, p = 0.039). Receiver operating characteristics (ROC) curves for disease-free survival (DFS) and disease-specific survival (DSS) identified SUVmax of 6.0 as optimal cut-off. Multivariate analysis showed that SUVmax ≥ 6.0 was an independent predictor of poor DFS (HR 2.288, p = 0.024) and DSS (HR 4.875, p. <. 0.001). The combination of SUVmax ≥6.0 with CA19.9 ≥200. U/ml was significantly associated with survival outcomes in comparison to patients without concordantly elevated values. Conclusion: SUVmax ≥6.0 is an independent predictor of DFS and DSS in resected PDAC. 18FDG-PET/CT might be considered in the preoperative evaluation of patients with pancreatic cancer. {\circledC} 2017 Editrice Gastroenterologica Italiana S.r.l.",
author = "I Pergolini and S Crippa and Matteo Salgarello and G Belfiori and S Partelli and G Ruffo and A Pucci and Giuseppe Zamboni and M Falconi",
year = "2018",
doi = "10.1016/j.dld.2017.09.122",
language = "English",
volume = "50",
pages = "84--90",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer

AU - Pergolini, I

AU - Crippa, S

AU - Salgarello, Matteo

AU - Belfiori, G

AU - Partelli, S

AU - Ruffo, G

AU - Pucci, A

AU - Zamboni, Giuseppe

AU - Falconi, M

PY - 2018

Y1 - 2018

N2 - Background: (18)fluoro-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) might be a useful tool in the management of pancreatic ductal adenocarcinoma (PDAC). Aims: The aim of this study was to analyze maximum standard uptake value (SUVmax) after 18FDG-PET/CT as predictor of survival outcomes and method to determine treatment strategies. Methods: A consecutive series of patients who underwent preoperative 18FDG-PET/CT and subsequent resection for PDAC were retrospectively reviewed. Patients who underwent neoadjuvant chemotherapy were excluded. Results: 46 patients were included in the analysis. Median follow-up was 27 months (4-67). Patients who recurred within 12 months showed a significantly higher preoperative median SUVmax (8.1 vs 6.1, p = 0.039). Receiver operating characteristics (ROC) curves for disease-free survival (DFS) and disease-specific survival (DSS) identified SUVmax of 6.0 as optimal cut-off. Multivariate analysis showed that SUVmax ≥ 6.0 was an independent predictor of poor DFS (HR 2.288, p = 0.024) and DSS (HR 4.875, p. <. 0.001). The combination of SUVmax ≥6.0 with CA19.9 ≥200. U/ml was significantly associated with survival outcomes in comparison to patients without concordantly elevated values. Conclusion: SUVmax ≥6.0 is an independent predictor of DFS and DSS in resected PDAC. 18FDG-PET/CT might be considered in the preoperative evaluation of patients with pancreatic cancer. © 2017 Editrice Gastroenterologica Italiana S.r.l.

AB - Background: (18)fluoro-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) might be a useful tool in the management of pancreatic ductal adenocarcinoma (PDAC). Aims: The aim of this study was to analyze maximum standard uptake value (SUVmax) after 18FDG-PET/CT as predictor of survival outcomes and method to determine treatment strategies. Methods: A consecutive series of patients who underwent preoperative 18FDG-PET/CT and subsequent resection for PDAC were retrospectively reviewed. Patients who underwent neoadjuvant chemotherapy were excluded. Results: 46 patients were included in the analysis. Median follow-up was 27 months (4-67). Patients who recurred within 12 months showed a significantly higher preoperative median SUVmax (8.1 vs 6.1, p = 0.039). Receiver operating characteristics (ROC) curves for disease-free survival (DFS) and disease-specific survival (DSS) identified SUVmax of 6.0 as optimal cut-off. Multivariate analysis showed that SUVmax ≥ 6.0 was an independent predictor of poor DFS (HR 2.288, p = 0.024) and DSS (HR 4.875, p. <. 0.001). The combination of SUVmax ≥6.0 with CA19.9 ≥200. U/ml was significantly associated with survival outcomes in comparison to patients without concordantly elevated values. Conclusion: SUVmax ≥6.0 is an independent predictor of DFS and DSS in resected PDAC. 18FDG-PET/CT might be considered in the preoperative evaluation of patients with pancreatic cancer. © 2017 Editrice Gastroenterologica Italiana S.r.l.

U2 - 10.1016/j.dld.2017.09.122

DO - 10.1016/j.dld.2017.09.122

M3 - Article

VL - 50

SP - 84

EP - 90

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 1

ER -